Analysts See $-0.43 EPS for Advaxis, Inc. (ADXS)

December 14, 2017 - By Adrian Erickson

 Analysts See $ 0.43 EPS for Advaxis, Inc. (ADXS)
Investors sentiment increased to 1.63 in 2017 Q2. Its up 0.47, from 1.16 in 2017Q1. It improved, as 8 investors sold Advaxis, Inc. shares while 19 reduced holdings. 15 funds opened positions while 29 raised stakes. 19.46 million shares or 9.11% less from 21.41 million shares in 2017Q1 were reported.
Cap Financial Advisers Limited Liability Corporation has 37,544 shares. Wells Fargo & Mn stated it has 44,813 shares. Jefferies Llc reported 85,479 shares. 5,316 are held by Victory Capital. Dafna Capital Mngmt Ltd Co has invested 1.14% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Focused Wealth Inc invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). National Bank & Trust Of New York Mellon Corporation stated it has 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). D E Shaw & Incorporated holds 0% or 256,105 shares. California State Teachers Retirement System invested in 0% or 64,641 shares. Moreover, Financial Bank Of Montreal Can has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Barclays Public Limited Co invested in 0% or 14,844 shares. Parametric Port Assocs Ltd Liability Corp holds 0% in Advaxis, Inc. (NASDAQ:ADXS) or 25,554 shares. Edge Wealth Ltd Llc holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 850 shares. State Board Of Administration Of Florida Retirement Systems invested in 20,505 shares. The New York-based Blackrock has invested 0% in Advaxis, Inc. (NASDAQ:ADXS).

Since September 22, 2017, it had 0 insider purchases, and 2 insider sales for $8.05 million activity.

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.43 EPS on January, 8.After having $-0.80 EPS previously, Advaxis, Inc.’s analysts see -46.25 % EPS growth. The stock increased 6.67% or $0.2 during the last trading session, reaching $3.2. About 720,574 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since December 14, 2016 and is uptrending. It has underperformed by 5.69% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 7 analyst reports since September 11, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Advaxis, Inc. (NASDAQ:ADXS) on Thursday, July 6 with “Buy” rating. Barclays Capital initiated it with “Overweight” rating and $40 target in Tuesday, September 22 report. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Friday, September 11 by Guggenheim. The stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Buy” rating by H.C. Wainwright on Wednesday, November 8. As per Wednesday, May 31, the company rating was maintained by Cantor Fitzgerald. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Monday, June 12 by Cantor Fitzgerald. The stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Buy” rating by H.C. Wainwright on Wednesday, June 14.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $131.41 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.